Public Employees Retirement System of Ohio Sells 2,047 Shares of Natera, Inc. (NASDAQ:NTRA)

Public Employees Retirement System of Ohio cut its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 4.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,106 shares of the medical research company’s stock after selling 2,047 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Natera were worth $5,218,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wealth Enhancement Advisory Services LLC increased its position in shares of Natera by 59.6% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,218 shares of the medical research company’s stock worth $998,000 after purchasing an additional 3,442 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in Natera by 50.6% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 13,622 shares of the medical research company’s stock worth $1,475,000 after buying an additional 4,575 shares during the last quarter. Swedbank AB acquired a new stake in Natera in the second quarter valued at $2,166,000. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Natera by 39.5% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 517,941 shares of the medical research company’s stock valued at $56,088,000 after acquiring an additional 146,670 shares during the period. Finally, First Citizens Bank & Trust Co. bought a new position in shares of Natera in the 2nd quarter valued at about $550,000. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Canaccord Genuity Group raised their target price on shares of Natera from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. The Goldman Sachs Group raised their price objective on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. TD Cowen boosted their target price on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Piper Sandler raised their price target on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. Finally, Craig Hallum increased their price objective on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $152.67.

Natera Stock Up 0.1 %

Shares of NTRA opened at $166.55 on Friday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12 month low of $57.22 and a 12 month high of $175.63. The firm’s 50 day moving average is $144.02 and its 200-day moving average is $124.56. The stock has a market capitalization of $21.99 billion, a PE ratio of -94.63 and a beta of 1.63.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s revenue was up 63.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.95) EPS. Equities research analysts forecast that Natera, Inc. will post -1.61 EPS for the current year.

Insider Buying and Selling at Natera

In other Natera news, insider Solomon Moshkevich sold 1,196 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $118.21, for a total value of $141,379.16. Following the sale, the insider now owns 110,695 shares of the company’s stock, valued at approximately $13,085,255.95. This trade represents a 1.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Rowan E. Chapman sold 1,767 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $170.24, for a total value of $300,814.08. Following the transaction, the director now directly owns 6,202 shares of the company’s stock, valued at $1,055,828.48. This trade represents a 22.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 137,987 shares of company stock valued at $21,895,591 in the last ninety days. 7.60% of the stock is currently owned by company insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.